1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Beam Picks Crowded AAT Field To Prove Its In Vivo Gene Editing

Base Editing Could Trump Existing Approaches

 
• By Andrew McConaghie

With its first US study for a base-edited CAR-T therapy now back on track, Beam Therapeutics is gearing up to begin studies of its first in vivo candidate, BEAM-302, next year in AAT.

Beam Therapeutics

Beam Therapeutics, a pioneer in the gene editing field of base editing, has unveiled early data from its first in vivo candidate, BEAM-302, which it hopes to take into the clinic next year.

While most competitors in the genetic therapy field are concentrating on ex vivo treatments, as these potentially carry less risk...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.